European Federation Of Allergy And Airway Diseases Patients Association

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

European Federation Of Allergy And Airway Diseases Patients Association

Established in 1991 in Stockholm, Sweden, The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is an independent non-profit organisation. The central office of EFA is located in Brussels, Belgium. EFA represent almost 30% of European citizens living with over 30 allergy, asthma and chronic obstructive pulmonary disease (COPD) diseases.

EFA being a European patient-led advocacy and action organisation strives to involve patients with asthma, COPD and allergy in European decisions that influence their health. Through its members, EFA advocate and try to ensure that the right of people with asthma, COPD and allergy to get best quality of care and to live uncompromised lives is guaranteed by EU decision-makers. EFA currently has 41 members in 25 European countries.

Healthcare being one of the key work of EFA, our main priorities are as follows:

  • To Adopt an EU strategy on major chronic diseases with disease specific instructions.
  • To strengthen patients’ safety during the treatment, improve accuracy and quality of information provided to patients, boost health literacy and patients’ participation in various decision-making tasks for betterment of health and lifestyle.
  • To ensure accurate and early diagnosis of allergies and chronic respiratory diseases through increased training for healthcare professionals by providing modern techniques, development of various national programmes, registering patients for spirometry testing
  • To eliminate discrimination of patients based on their financial status, disease or condition and to provide quality treatment to all.
  • To provide more funds for EU health policy, programmes and prioritise investments in research studies of allergic and chronic respiratory diseases.
Read More»